XPO1 (Exportin-1) has been recognized as a potential therapeutic target in multiple tumor types, including AML, and the magnitude of its overexpression at an mRNA and protein level has been directly correlated with poor overall survival. The gene discussed is XPO1; the disease is neoplasm.